This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pfizer's Cardiomyopathy Drug Vyndaqel Gets Approval in Europe
by Zacks Equity Research
Pfizer's (PFE) Vyndaqel gets approval in Europe and becomes the first therapy approved to treat ATTR-CM in the continent.
Glaxo Underperforms Industry in a Year: What's in Store?
by Zacks Equity Research
Shares of Glaxo (GSK) lag the industry in a year as generic erosion of some drugs mainly its top-selling drug, Advair offsets strong sales of new drugs.
Mylan (MYL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on merger with Upjohn, when Mylan (MYL) reports Q4 results.
What Poses the Greatest Risk to Markets?
by John Blank
The Nov. election, coronavirus, or earnings results?
Deciphera's NDA for GIST Drug Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts Deciphera's (DCPH) NDA for ripretinib and grants a priority review to the same for the treatment of advanced gastrointestinal stromal tumors.
Merck's Keytruda Meets PFS Endpoint in Breast Cancer Study
by Zacks Equity Research
Merck's (MRK) immuno-oncology drug, Keytruda, significantly improves progression free survival as first-line treatment for metastatic triple-negative breast cancer patients in a pivotal study.
Pfizer's Xtandi Improves OS Rate in Prostate Cancer Study
by Zacks Equity Research
Pfizer's (PFE) Xtandi demonstrates a significant improvement in overall survival in the late-stage PROSPER study that evaluated the drug in men with non-metastatic castration-resistant prostate cancer.
The Zacks Analyst Blog Highlights: Microsoft, JP Morgan Chase and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, JP Morgan Chase and Pfizer
Coronavirus Update: Global Week Ahead
by John Blank
In the Global Week Ahead, the global economy and China will be reeling from the spread of a novel pneumonia or flu-like coronavirus.
Blueprint Medicines' NDA for Avapritinib Gets Extended Review
by Zacks Equity Research
FDA extends review period for Blueprint Medicines' (BPMC) NDA seeking accelerated approval for avapritinib in fourth-line gastrointestinal stromal tumors by three months.
Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.
Glaxo (GSK) Lags Q4 Earnings & Revenue Estimates, Stock Down
by Zacks Equity Research
Glaxo (GSK) misses on earnings and sales in the fourth quarter. The company expects earnings to decline in 2020.
Novo Nordisk (NVO) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Novo Nordisk (NVO) posts in-line earnings, while revenues beat estimates in the fourth quarter of 2019.
Merck's Recarbrio Gets FDA Priority Review for New Indication
by Zacks Equity Research
The FDA accepts Merck's (MRK) sNDA for antibacterial injection Recarbrio and grants priority review.
Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q4 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Opdivo, Revlimid and Eliquis along with the regular top and bottom-line numbers when Bristol-Myers (BMY) reports fourth-quarter results.
The Zacks Analyst Blog Highlights: Amazon.com, Procter & Gamble, Pfizer, Southwest Airlines and Humana
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon.com, Procter & Gamble, Pfizer, Southwest Airlines and Humana
3 Dividend-Paying Stocks for Investors to Buy to Fight Off Market Uncertainty
by Benjamin Rains
Check out these three dividend-paying stocks that investors might want to buy to help combat coronavirus-based market pullback fears...
Bristol-Myers' Opdivo-Yervoy NSCLC Application in EU Withdrawn
by Zacks Equity Research
Bristol-Myers (BMY) has withdrawn its application in the EU for the Opdivo and Yervoy combo for the treatment of advanced NSCLC based on data from the CheckMate-227 study.
Is a Disappointment in Store for Glaxo's (GSK) Q4 Earnings?
by Zacks Equity Research
Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales in the fourth quarter.
Q4 Earnings Scorecard and Analyst Reports for Amazon, Pfizer & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), The Procter & Gamble Company (PG) and Pfizer Inc. (PFE).
Lilly's Olumiant Succeeds in Another Late-Stage Eczema Study
by Zacks Equity Research
Lilly's (LLY) JAK inhibitor Olumiant meets primary endpoint of phase III BREEZE-AD5 study, evaluating the drug as a monotherapy in atopic dermatitis patients.
Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative
by Kinjel Shah
Lilly (LLY), Pfizer (PFE) and Novartis (NVS) announce Q4 results.
Bayer Seeks FDA Approval for New Formulation of Nifurtimox
by Zacks Equity Research
Bayer (BAYRY) files application to the FDA for the new formulation of nifurtimox to improve the body-weight adjusted dosing in pediatric Chagas patients.
Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More
by Zacks Equity Research
Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.
Merck's Dificid Gets FDA Approval in Pediatric Indication
by Indrajit Bandyopadhyay
The FDA grants approval to Merck's (MRK) two regulatory applications seeking expanded approval for its antibacterial medicine, Dificid.